Business Combination - Intangible Assets Acquired (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | 15 Months Ended | |
|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Jun. 30, 2026 |
Jun. 30, 2026 |
Sep. 30, 2026 |
Dec. 31, 2025 |
Dec. 31, 2025 |
|
| Indefinite-Lived Intangible Assets [Roll Forward] | ||||||
| Impairment | $ 0 | $ 9,200,000 | $ 9,190,897 | $ 0 | ||
| Goodwill | ||||||
| Combination Date Fair Value | $ 12,401,118 | 12,401,118 | ||||
| Impairment | 0 | $ 0 | 0 | 0 | ||
| Carrying Value | 11,979,823 | 11,979,823 | 12,401,118 | $ 12,401,118 | ||
| Pharmagesic | ||||||
| Indefinite-Lived Intangible Assets [Roll Forward] | ||||||
| Combination Date Fair Value | 68,985,026 | 68,985,026 | 69,500,000 | |||
| Impairment | (9,190,897) | |||||
| Translation Adj | (2,357,837) | (514,974) | ||||
| Carrying Value | 57,436,292 | 57,436,292 | 68,985,026 | 68,985,026 | ||
| Goodwill | ||||||
| Combination Date Fair Value | 12,401,118 | 12,401,118 | 12,493,727 | |||
| Translation Adj | (421,295) | (92,609) | ||||
| Carrying Value | 11,979,823 | 11,979,823 | 12,401,118 | 12,401,118 | ||
| Pharmagesic | Halneuron for Cancer Related Pain | ||||||
| Indefinite-Lived Intangible Assets [Roll Forward] | ||||||
| Combination Date Fair Value | 59,456,159 | 59,456,159 | 59,900,000 | |||
| Translation Adj | (2,019,867) | (443,841) | ||||
| Carrying Value | $ 57,436,292 | 57,436,292 | 59,456,159 | 59,456,159 | ||
| Pharmagesic | Halneuron for Chemotherapy Induced Neuropathic Pain | ||||||
| Indefinite-Lived Intangible Assets [Roll Forward] | ||||||
| Combination Date Fair Value | $ 9,528,867 | 9,528,867 | 9,600,000 | |||
| Impairment | (9,190,897) | |||||
| Translation Adj | $ (337,970) | (71,133) | ||||
| Carrying Value | $ 9,528,867 | $ 9,528,867 | ||||
| X | ||||||||||
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) from foreign currency translation and measurement period adjustments of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of impairment loss for indefinite-lived intangible asset. Excludes goodwill. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of indefinite-lived intangible asset. Excludes goodwill. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in indefinite-lived intangible asset from foreign currency translation and measurement period adjustments. Excludes goodwill. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|